| Cape Regency Rehabilitation & Health Care Center | |
| 120 S Main Street, Centerville, Massachusetts 02632 | |
| (508) 778-1835 | |
| Name | Cape Regency Rehabilitation & Health Care Center |
|---|---|
| Location | 120 S Main Street, Centerville, Massachusetts |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 120 |
| Occupancy Rate | 66.42% |
| Medicare ID (CCN) | 225338 |
| Legal Business Name | Cape Regency Ma Snf Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1942299185 |
| Organization Name | CAPE REGENCY MA SNF LLC |
| Doing Business As | CAPE REGENCY REHABILITATION & HEALTH CARE CENTER |
| Address | 120 South Main Street, Centerville, MA 02632 |
| Phone Number | 508-778-1835 |
News Archive
Economists and researchers long have blamed the high cost of health care in Northern California on the giant medical systems that have gobbled up hospitals and physician practices — most notably Sutter Health, a nonprofit chain with 24 hospitals, 34 surgery centers and 5,000 physicians across the region.
POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, presented positive results from two pivotal Phase 3 clinical trials of the investigational product, PA32540, at The American Heart Association (AHA) Scientific Sessions 2012, as Poster #12057: Treatment Continuation and Cardiovascular Safety of Antiplatelet Therapy with PA32540, A Tablet with Enteric-Coated Aspirin and Immediate-Release Omeprazole: Results of Two 6-Month, Phase 3 Studies.
Living Cell Technologies announced pre-clinical results today showing its brain protection product, NeurotrophinCell (NtCell) produces a marked reduction in the size of brain lesions in a Huntington's disease (HD) model.
In a paper published in today's online issue of the Journal of Alzheimer's Disease (DOI 10.3233/JAD-190772), TauRx has reported unexpected results of a pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological activity of the drug hydromethylthionine on the brain in over 1,000 patients with mild-to-moderate Alzheimer's disease.
PDI, Inc. today announced the launch of a new division, EngageCE, that will offer expert clinical educators to work with health care providers in the management of chronic diseases in order to optimize patient care and outcomes.
› Verified 7 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Economists and researchers long have blamed the high cost of health care in Northern California on the giant medical systems that have gobbled up hospitals and physician practices — most notably Sutter Health, a nonprofit chain with 24 hospitals, 34 surgery centers and 5,000 physicians across the region.
POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, presented positive results from two pivotal Phase 3 clinical trials of the investigational product, PA32540, at The American Heart Association (AHA) Scientific Sessions 2012, as Poster #12057: Treatment Continuation and Cardiovascular Safety of Antiplatelet Therapy with PA32540, A Tablet with Enteric-Coated Aspirin and Immediate-Release Omeprazole: Results of Two 6-Month, Phase 3 Studies.
Living Cell Technologies announced pre-clinical results today showing its brain protection product, NeurotrophinCell (NtCell) produces a marked reduction in the size of brain lesions in a Huntington's disease (HD) model.
In a paper published in today's online issue of the Journal of Alzheimer's Disease (DOI 10.3233/JAD-190772), TauRx has reported unexpected results of a pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological activity of the drug hydromethylthionine on the brain in over 1,000 patients with mild-to-moderate Alzheimer's disease.
PDI, Inc. today announced the launch of a new division, EngageCE, that will offer expert clinical educators to work with health care providers in the management of chronic diseases in order to optimize patient care and outcomes.
› Verified 7 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $42413 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 21.03 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 1.66 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 92.48 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.38 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 5.02 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 71.24 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 32.32 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 56.88 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.96 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 26.49 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 28 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 3.45 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 93.23 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 58.6 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 72.06 | 82.93 |
News Archive
Economists and researchers long have blamed the high cost of health care in Northern California on the giant medical systems that have gobbled up hospitals and physician practices — most notably Sutter Health, a nonprofit chain with 24 hospitals, 34 surgery centers and 5,000 physicians across the region.
POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, presented positive results from two pivotal Phase 3 clinical trials of the investigational product, PA32540, at The American Heart Association (AHA) Scientific Sessions 2012, as Poster #12057: Treatment Continuation and Cardiovascular Safety of Antiplatelet Therapy with PA32540, A Tablet with Enteric-Coated Aspirin and Immediate-Release Omeprazole: Results of Two 6-Month, Phase 3 Studies.
Living Cell Technologies announced pre-clinical results today showing its brain protection product, NeurotrophinCell (NtCell) produces a marked reduction in the size of brain lesions in a Huntington's disease (HD) model.
In a paper published in today's online issue of the Journal of Alzheimer's Disease (DOI 10.3233/JAD-190772), TauRx has reported unexpected results of a pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological activity of the drug hydromethylthionine on the brain in over 1,000 patients with mild-to-moderate Alzheimer's disease.
PDI, Inc. today announced the launch of a new division, EngageCE, that will offer expert clinical educators to work with health care providers in the management of chronic diseases in order to optimize patient care and outcomes.
› Verified 7 days ago
Cape Regency Rehabilitation & Health Care Center Location: 120 S Main Street, Centerville, Massachusetts 02632 Phone: (508) 778-1835 |